Scottish biotechnology company OncoBioPharm has announced that from today it will operate as aTen Therapeutics Ltd. aTen (pronounced ‘atten’) refers to the angiotensin pathway, which plays a key role in several major diseases, and is the target of the company’s lead antibody candidate, Tensinomab.

The new name reflects the company’s commitment to exploring the full potential of its innovative technology platform, not only within oncology but across other major disease areas.